SpringerLink
Log in

Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The genomic landscape of oesophagogastric (OG) cancer is highly complex. The recent elucidation of some of the pathways involved has suggested a number of novel targets for therapy. This therapy is urgently required as with conventional chemotherapy regimens patients with advanced OG cancer still have a median overall survival of under a year. This review outlines the rationale for the current treatment of OG cancer with chemotherapy and describes both previously conducted and ongoing clinical trials of novel agents in this area. The targets and associated treatments discussed include HER-2, EGFR, VEGF, c-Met, FGFR-2, PI3K, mTOR andIGF-1. To date only two targeted treatments, trastuzumab and ramucirumab, have become part of the treatment paradigm for OG cancer, partly due to difficulties in defining predictive biomarkers in this disease. However, there are a number of promising drugs in the pipeline and this article seeks to describe these and other potential novel approaches including targeting DNA repair deficiencies and the immune system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136:E359–86.

    Article  PubMed  CAS  Google Scholar 

  2. Shah MA, Kelsen DP. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw. 2010;8:437–47.

    PubMed  CAS  Google Scholar 

  3. Cancer Research UK. http://www.cancerresearchuk.org/. Accessed 20 Oct 2015.

  4. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12:354–62.

    PubMed  PubMed Central  Google Scholar 

  5. Wagner AD, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903–9.

    Article  PubMed  CAS  Google Scholar 

  6. Ajani JA, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007;25:3210–6.

    Article  PubMed  CAS  Google Scholar 

  7. Cunningham D, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.

    Article  PubMed  CAS  Google Scholar 

  8. Kim HS, et al. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Ann Oncol. 2013;24:2850–4.

    Article  PubMed  CAS  Google Scholar 

  9. Kang JH, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30:1513–8.

    Article  PubMed  CAS  Google Scholar 

  10. Thuss-Patience PC, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47:2306–14.

    Article  PubMed  CAS  Google Scholar 

  11. Ford HER, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15:78–86.

    Article  PubMed  CAS  Google Scholar 

  12. Hironaka S, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 tria. J Clin Oncol. 2013;31:4438–44.

    Article  PubMed  CAS  Google Scholar 

  13. Wilke H, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–35.

    Article  PubMed  CAS  Google Scholar 

  14. Bass AJ, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.

    Article  PubMed Central  CAS  Google Scholar 

  15. Deng N, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012;61:673–84.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol. 2003;30:3–14.

    Article  CAS  Google Scholar 

  17. Jørgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer—a systematic analysis of data from the literature. J Cancer. 2012;3:137–44. doi:10.7150/jca.4090.

  18. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523–9.

    Article  PubMed  CAS  Google Scholar 

  19. Hofmann M, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797–805.

    Article  PubMed  CAS  Google Scholar 

  20. Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

    Article  PubMed  CAS  Google Scholar 

  21. Rivera F, et al. NeoHx study: perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma—R0 resection, pCR, and toxicity analysis. 2013 ASCO. J Clin Oncol. 2013;31(suppl abstr 4098).

  22. Hofheinz R, et al. HER-FLOT: trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: a phase II trial of the AIO Gastric Cancer Study Group. 2014 ASCO. J Clin Oncol. 2014;32 suppl(abstr 4073).

  23. Kang Y-K, et al. A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. Br J Cancer. 2014;111:660–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16:209.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Hecht J, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. 2013 ASCO Abstracts. J Clin Oncol. 2013;31(suppl; abstr LBA4001).

  26. Satoh T, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study. J Clin Oncol. 2014;32:2039–49.

    Article  PubMed  CAS  Google Scholar 

  27. Janjigian YY, et al. A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab-refractory esophagogastric (EG) cancer. 2013 ASCO Abstracts. J Clin Oncol. 2013;31(suppl:Abstract e15017).

  28. Oh DY, et al. A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen. 2012 Gastrointestinal Cancers Symposium. J Clin Oncol. 2012;30(suppl 4:Abstract 54).

  29. Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol. Syst. Biol. 2005;1:2005.0010.

  30. Begnami MD, et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol. 2011;29:3030–6.

    Article  PubMed  CAS  Google Scholar 

  31. Kim MA, et al. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology. 2008;52:738–46.

    Article  PubMed  CAS  Google Scholar 

  32. Lordick F, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:490–9.

    Article  PubMed  CAS  Google Scholar 

  33. Waddell T, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:481–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Suntharalingham M, et al. The initial report of RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery. 2014 Gastrointestinal Cancers Symposium. J Clin Oncol. 2014;(suppl 3, abstr LBA6).

  35. Crosby T, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 2013;14:627–37.

    Article  PubMed  CAS  Google Scholar 

  36. Dragovich T, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol. 2006;24:4922–7.

    Article  PubMed  CAS  Google Scholar 

  37. Dutton SJ, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol. 2014;15:894–904.

    Article  PubMed  CAS  Google Scholar 

  38. Petty R, Dahle-Smith A, M. Z. et al. Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in esophageal cancer (EC): results of a biomarker analysis of a phase III trial of gefitinib versus placebo (TRANS-COG). 2014 ASCO Abstracts. J Clin Oncol. 2014(suppl; abstr 4016).

  39. Aprile G, et al. Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: a critical insight. Crit Rev Oncol Hematol. 2015;95:165–78.

    Article  PubMed  Google Scholar 

  40. Lieto E, et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol. 2008;15:69–79.

    Article  PubMed  Google Scholar 

  41. Peng L, et al. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis. Mol Biol Rep. 2012;39:9473–84.

    Article  PubMed  CAS  Google Scholar 

  42. Ohtsu A. et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29:3968–3976.

  43. Shen L, et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 2014;18:168–76.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012;30:2119–27.

    Article  PubMed  CAS  Google Scholar 

  45. Fuchs CS, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–9.

    Article  PubMed  CAS  Google Scholar 

  46. Al-Batran S, et al. RAINBOW: a global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results. 2014 AS. J Clin Oncol. 2014; 2:5s(suppl; abstr 4004).

  47. Yoon H, et al. Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial. 2014 ASCO Abstracts. J Clin Oncol. 2014;32:5s(suppl; abstr 4004).

  48. Qin S. Phase III study of apatinib in advanced gastric cancer: a randomized, double-blind, placebo-controlled trial. 2014 ASCO Abstracts. J Clin Oncol. 2014;32:5s(suppl; abstr 4003).

  49. Nakajima M, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer. 1999;85:1894–902.

    Article  PubMed  CAS  Google Scholar 

  50. Jhawer M, et al. Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. 2009 ASCO Abstracts. J Clin Oncol. 2009;27:15s(suppl; abstr 4502).

  51. Kwak EL, et al. Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer. 2015 Gastrointestinal Cancers Symposium. J Clin Oncol 2015;33(suppl 3; abstr 1).

  52. Cunningham D, et al. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J Clin Oncol 2015;33(suppl; abstr 4000).

  53. Cunningham D, et al. MetGastric: a randomized phase III study of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction. 2013 ASCO Annual Meeting. J Clin Oncol. 2013;31(suppl; abstr TPS4155).

  54. Shah M, et al. Randomized phase II study of FOLFOX ± MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC). 2015 Gastrointestinal Cancers Symposium. J Clin Oncol. 2015;33(suppl3, abstr2).

  55. Su X, et al. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br J Cancer. 2014;110:967–75.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Oki E, et al. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer. 2005;117:376–80.

    Article  PubMed  CAS  Google Scholar 

  57. Okines AFC, et al. Biomarker analysis in oesophagogastric cancer: results from the REAL3 and TransMAGIC trials. Eur J Cancer. 2013;49:2116–25.

    Article  PubMed  CAS  Google Scholar 

  58. Yu G, et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res. 2009;15:1821–9.

    Article  PubMed  CAS  Google Scholar 

  59. Ohtsu A, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013;31:3935–3943.

  60. Lee SJ, et al. Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. Invest New Drugs. 2013;31:1580–6.

    Article  PubMed  CAS  Google Scholar 

  61. Yoon DH, et al. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer. 2012;106:1039–44.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. Zhang C-Η, Awasthi N, Schwarz MA, Schwarz RE. The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer. Int J Oncol. 2013;43:1627–35.

    PubMed Central  CAS  Google Scholar 

  63. Fuereder T, et al. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake. Clin Cancer Res. 2011;17:5322–32.

    Article  PubMed  CAS  Google Scholar 

  64. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer. 2003;107:873–7.

    Article  PubMed  CAS  Google Scholar 

  65. Matsubara J, et al. Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology. 2008;74:76–83.

    Article  PubMed  CAS  Google Scholar 

  66. Molife LR, et al. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer. 2010;103:332–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  67. Heitz F, et al. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy. Expert Rev Anticancer Ther. 2010;10:1125–36.

    Article  PubMed  CAS  Google Scholar 

  68. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26:3785–90.

    Article  PubMed  CAS  Google Scholar 

  69. Kubota E, et al. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines. Cell Cycle. 2014;13:2129–37.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  70. Bang Y-J, et al. Randomized, double-blind phase II trial with prospective classification by atm protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer. J Clin Oncol. 2015. doi:10.1200/JCO.2014.60.0320.

    Google Scholar 

  71. Guo X, et al. Abstract B42: ATM deficiency sensitizes gastric cancer cells to the PARP inhibitior olaparib. Mol Cancer Ther. 2009;8:B42–B42.

    Article  Google Scholar 

  72. Kang B, et al. Expression status of ataxia-telangiectasia-mutated gene correlated with prognosis in advanced gastric cancer. Mutat Res. 2008;638:17–25.

    Article  PubMed  CAS  Google Scholar 

  73. Kim HS, Choi SI, Min HL, Kim MA, Kim WH. Mutation at intronic repeats of the ataxia-telangiectasia mutated (ATM) gene and ATM protein loss in primary gastric cancer with microsatellite instability. PLoS One. 2013;8:e82769.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Bang YJ, et al. Olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer: a randomized, double-blind phase II study. 2013 ASCO Annual Meeting, Abstracts, Meeting Library. J Clin Oncol. 2013;31(suppl;abstr 4013).

  75. Muro K, et al. A phase 1b study of pembrolizumab (Pembro; MK-3475) in patients (PTS) with advanced gastric cancer. Ann Oncol. 2014;25(5):1–41.

  76. Tirkes T, et al. Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics. 2013;33(5):1323–41.

Download references

Acknowledgments

The authors acknowledge support from the NIHR RM/ICR Biomedical Research Centre.

Author information

Authors and Affiliations

  1. Gastrointestinal Unit, Department of Medicine, Royal Marsden Hospital, Down’s Road, Sutton, Surrey, SM2 5PT, UK

    Kate Young & Ian Chau

Authors
  1. Kate Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ian Chau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian Chau.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Young, K., Chau, I. Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions. Drugs 76, 13–26 (2016). https://doi.org/10.1007/s40265-015-0510-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0510-y

Keywords

Search

Navigation